41 patents
Page 2 of 3
Utility
Bacteria Engineered to Treat Disorders In Which Oxalate Is Detrimental
28 Jul 22
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme.
Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
Filed: 2 Feb 22
Utility
Bacteria Engineered to Treat Metabolic Diseases
21 Jul 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Elizabeth Rowe, Yves Millet, Adam B. Fisher
Filed: 26 Jan 22
Utility
Synergistic Combinations of Arginine-producing Bacteria And/or Ammonia-consuming Bacteria and Checkpoint Inhibitors and Methods of Use Thereof
21 Jul 22
Disclosed herein are synergistic compositions and methods using arginine-producing bacteria and/or ammonia-consuming bacteria in combination with a checkpoint inhibitor for use in treating cancer.
Jose M. Lora, Roger Geiger
Filed: 13 May 20
Utility
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
12 Jul 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Filed: 8 Sep 16
Utility
Bacteria Engineered to Treat Disorders Involving the Catabolism of a Branched Chain Amino Acid
2 Jun 22
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off.
Dean Falb, Paul F. Miller, Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Alex Tucker
Filed: 10 Dec 21
Utility
Bacteria engineered to treat metabolic diseases
5 Apr 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet, Adam Fisher
Filed: 24 Jun 16
Utility
Bacteria engineered to treat disorders in which oxalate is detrimental
15 Mar 22
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme.
Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
Filed: 31 Aug 16
Utility
Combination Therapies of Microorganisms and Immune Modulators for Use In Treating Cancer
27 Jan 22
Combination therapies comprising a microorganism and an immune modulator, and methods of modulating and treating cancers are disclosed.
Jose M. Lora, Anna Sokolovska
Filed: 8 Nov 19
Utility
Surface Display of Proteins on Recombinant Bacteria and Uses Thereof
2 Dec 21
Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.
Ning Li
Filed: 26 May 21
Utility
Bacteria engineered to treat diseases associated with hyperammonemia
13 Jul 21
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Dean Falb, Vincent M Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Filed: 18 May 17
Utility
Bacteria Engineered to Treat Diseases Associated with Hyperammonemia
17 Jun 21
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Filed: 16 Dec 20
Utility
Bacteria Engineered to Treat a Disease or Disorder
10 Jun 21
Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
Filed: 17 Dec 20
Utility
Bacteria Engineered to Treat Diseases That Benefit from Reduced Gut Inflammation And/or Tightened Gut Mucosal Barrier
3 Jun 21
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Paul F. Miller, Vincent M. Isabella, Jonathan W. Kotula, Dean Falb, Adam B. Fisher, Yves Millet, Ning Li
Filed: 3 Feb 17
Utility
Bacteria Engineered to Treat Liver Disease
27 May 21
The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts.
Paul F. Miller, Vincent M. Isabella, Dean Falb, Jonathan W. Kotula, Yossi Dagon
Filed: 31 May 19
Utility
Engineered Bacteria Expressing Racemase for Treating Diseases Associated with Hyperammonemia
6 May 21
Disclosed herein are bacteria engineered to treat diseases associated with hyperammonemia and methods of use thereof.
Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Dean Falb
Filed: 2 Nov 18
Utility
Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
1 Apr 21
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
Filed: 1 May 20
Utility
Bacteria engineered to treat a disease or disorder
2 Mar 21
Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
Filed: 22 Dec 17
Utility
Bacteria Engineered to Reduce Hyperphenylalaninemia
5 Aug 20
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
Filed: 11 Feb 20
Utility
Bacteria for the Treatment of Disorders
3 Jun 20
Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
Filed: 20 Jun 18
Utility
Microorganisms Programmed to Produce Immune Modulators and Anti-cancer Therapeutics In Tumor Cells
13 May 20
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Adam Fisher, Ning Li, Jose M. Lora
Filed: 10 Jul 18